CVE-2023-42435

CVE-2023-42435 is a medium-severity vulnerability in Dexma Dexgate with a CVSS 3.x base score of 5.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-352.

Key facts

Description

The affected product is vulnerable to a cross-site request forgery vulnerability, which may allow an attacker to perform actions with the permissions of a victim user.

Frequently asked questions

What is CVE-2023-42435?
The affected product is vulnerable to a cross-site request forgery vulnerability, which may allow an attacker to perform actions with the permissions of a victim user.
How severe is CVE-2023-42435?
CVE-2023-42435 has a CVSS 3.x base score of 5.5, rated medium severity. It is exploitable over network with low attack complexity, requires low privileges and user interaction. Impact on confidentiality is low, integrity low, and availability low.
Is CVE-2023-42435 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (8th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2023-42435?
CVE-2023-42435 affects Dexma Dexgate. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2023-42435?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.
When was CVE-2023-42435 published?
CVE-2023-42435 was published on 2023-10-19 and last updated on 2026-06-17.

References

Affected products (1)

More vulnerabilities in Dexma Dexgate

All CVEs affecting Dexma Dexgate →

Other CWE-352 (Cross-Site Request Forgery (CSRF)) vulnerabilities

Browse all CWE-352 (Cross-Site Request Forgery (CSRF)) vulnerabilities →